Impact of COVID-19 on mucormycosis presentation and laboratory values: A comparative analysis

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(5), P. e0321897 - e0321897

Published: May 2, 2025

Background The COVID-19 pandemic has led to an alarming increase in mucormycosis coinfections and its rapid progression. overlapping risk factors symptoms between further complicate prompt detection, which is crucial for patient survival. This study aims investigate potential differences progression, initial symptom presentation, laboratory value alterations patients with history enhance diagnostic accuracy improve outcomes this complex clinical scenario. Methodology retrospective cohort study, conducted from April 1, 2021, March 31, 2022, examined 102 diagnosed at two primary teaching hospitals. Patients were categorized into groups based on history. Variables included demographic information, parameters, results, outcomes. compared studies presentation history-positive history-negative groups, a particular focus mortality rates associated comorbidities such as diabetes, cancer immunosuppressive treatment. Results Initial presentations differed significantly, eneralized Estimating Equations (GEE) analysis, adjusted comorbidities, revealed was increased platelet counts (P = 0.0311) decreased facial swelling 0.049) fever reporting < 0.001). Cancer history, treatment also showed significant associations various parameters. Laboratory analysis without group lower WBC 0.002), higher hemoglobin levels 0.001) controls. Diabetes more prevalent patients, while common Conclusion reveals intricate relationships mucormycosis, challenging earlier findings. Mucormycosis exhibited altered presentation. research highlights varied patterns across subgroups underscores the complexity of interactions COVID-19, cancer, diabetes cases. These findings advocate multivariate analytical approaches better understand these multifaceted relationships.

Language: Английский

Survival and prognostic factors in rhino-orbito-cerebral mucormycosis: A 3-year cohort study

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: May 8, 2025

Mucormycosis, a severe fungal infection, has exhibited concerning increase in recent years, particularly during the COVID-19 outbreak. This three-year cohort study aims to investigate an overview of epidemiology, clinical and radiographic signs, treatment, prognosis Rhino-Orbito-Cerebral Mucormycosis (ROCM). prospective was conducted from 2019 2022 at Khalili Hospital Shiraz, Iran. It focused on proven cases ROCM. Patients underwent stepwise treatment protocol, with meticulous documentation findings ophthalmological examinations imaging studies. Additionally, follow-up period implemented monitor patient progress assess effectiveness strategies. Statistical analyses were performed using IBM SPSS statistics. In this study, 77 patients ROCM participated. Most presented facial pain (75.3%), swelling (62.3%), vision loss (51.9%). Treatment included combined antifungal therapy surgical debridement, 7.8% undergoing ocular exenteration. Notably, despite extensive disease, all that orbital exenteration survived 3-year follow-up. Impaired V2 nerve function associated higher mortality rates, presenting initial visual acuity No Light Perception (NLP) had compared those other degrees impairment. The convergence mucormycosis, specifically form ROCM, led outbreak characterized by high morbidity rates. meticulously documented long-term these patients, aiming provide novel insights into infection.

Language: Английский